Extensive Protein Expression Changes Induced by Pamidronate in RAW 264.7 Cells As Determined by IP-HPLC

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2020 Jun 9

PMID 32509464

Citations 5

Authors

Sang Shin Lee

Soung Min Kim

Yeon Sook Kim

Suk Keun Lee

Affiliations

Soon will be listed here.

Abstract

Background: Bisphosphonate therapy has become a popular treatment for osteoporosis, Paget's disease, multiple myeloma, osteogenesis imperfecta, myocardial infarction, and cancer despite its serious side effects. Bisphosphonate-induced molecular signaling changes in cells are still not clearly elucidated.

Methods: As bisphosphonates are primarily engulfed by macrophages, we treated RAW 264.7 cells (a murine macrophage cell line) with pamidronate and investigated global protein expressional changes in cells by immunoprecipitation high performance liquid chromatography (IP-HPLC) using 218 antisera.

Results: Pamidronate upregulated proliferation-activating proteins associated with p53/Rb/E2F and Wnt/β-catenin pathways, but downregulated the downstream of RAS signaling, pAKT1/2/3, ERK-1, and p-ERK-1, and subsequently suppressed cMyc/MAX/MAD network. However, in situ proliferation index of pamidronate-treated RAW264.7 cells was slightly increased by 3.2% vs. non-treated controls. Pamidronate-treated cells showed increase in the expressions of histone- and DNA methylation-related proteins but decrease of protein translation-related proteins. NFkB signaling was also suppressed as indicated by the down-regulations of p38 and p-p38 and the up-regulation of mTOR, while the protein expressions related to cellular protection, HSP-70, NRF2, JNK-1, and LC3 were upregulated. Consequently, pamidronate downregulated the protein expressions related to immediate inflammation,cellular differentiation, survival, angiogenesis, and osteoclastogenesis, but upregulated PARP-1 and FAS-mediated apoptosis proteins. These observations suggest pamidronate affects global protein expressions in RAW 264.7 cells by stimulating cellular proliferation, protection, and apoptosis but suppressing immediate inflammation, differentiation, osteoclastogenesis, and angiogenesis. Accordingly, pamidronate appears to affect macrophages in several ways eliciting not only its therapeutic effects but also atypical epigenetic modification, protein translation, RAS and NFkB signalings. Therefore, our observations suggest pamidronate-induced protein expressions are dynamic, and the affected proteins should be monitored by IP-HPLC to achieve the therapeutic goals during treatment.

Citing Articles

Crosstalk Between H-Type Vascular Endothelial Cells and Macrophages: A Potential Regulator of Bone Homeostasis.

Fan J, Xie Y, Liu D, Cui R, Zhang W, Shen M J Inflamm Res. 2025; 18:2743-2765.

PMID: 40026304 PMC: 11871946. DOI: 10.2147/JIR.S502604.

Clinical significance of drug cessation on medication-related osteonecrosis of the jaw in patients with osteoporosis.

Mustakim K, Eo M, Lee J, Seo M, Kim S J Korean Assoc Oral Maxillofac Surg. 2023; 49(2):75-85.

PMID: 37114445 PMC: 10151695. DOI: 10.5125/jkaoms.2023.49.2.75.

Significance of medication discontinuation on bisphosphonate-related jaw osteonecrosis in a rat model.

Mustakim K, Eo M, Oh J, Lee J, Myoung H, Kim S Sci Rep. 2022; 12(1):21449.

PMID: 36509781 PMC: 9744902. DOI: 10.1038/s41598-022-25347-3.

Pentoxifylline-induced protein expression change in RAW 264.7 cells as determined by immunoprecipitation-based high performance liquid chromatography.

Seo M, Kim D, Kim Y, Lee S PLoS One. 2022; 17(3):e0261797.

PMID: 35333871 PMC: 8956197. DOI: 10.1371/journal.pone.0261797.

Nrf2 in the Field of Dentistry with Special Attention to NLRP3.

Schieffer L, Manzl C, Schatz C, Haybaeck J, Crismani A Antioxidants (Basel). 2022; 11(1).

PMID: 35052653 PMC: 8772975. DOI: 10.3390/antiox11010149.

References

Kim M, Yoon C, Kim S, Park Y, Lee S, Lee S . Effects of 4-Hexylresorcinol on Protein Expressions in RAW 264.7 Cells as Determined by Immunoprecipitation High Performance Liquid Chromatography. Sci Rep. 2019; 9(1):3379. PMC: 6399215. DOI: 10.1038/s41598-019-38946-4. View

Clarke N, Tomlinson A, Ohyagi Y, Younkin S, Naylor S . Detection and quantitation of cellularly derived amyloid beta peptides by immunoprecipitation-HPLC-MS. FEBS Lett. 1998; 430(3):419-23. DOI: 10.1016/s0014-5793(98)00706-6. View

Jayasena A, Atapattu N, Lekamwasam S . Treatment of glucocorticoid-induced low bone mineral density in children: a systematic review. Int J Rheum Dis. 2015; 18(3):287-93. DOI: 10.1111/1756-185X.12560. View

Marx R, Tursun R . Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease. Int J Oral Maxillofac Surg. 2012; 41(3):283-9. DOI: 10.1016/j.ijom.2011.12.016. View

Chen C, Xia M, Wu L, Zhou C, Wang F . Modeling the interaction of seven bisphosphonates with the hydroxyapatite(100) face. J Mol Model. 2012; 18(9):4007-12. DOI: 10.1007/s00894-012-1398-z. View

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson D . Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991; 88(6):2095-105. PMC: 295810. DOI: 10.1172/JCI115539. View

Hong J, Nam W, Cha I, Chung S, Choi H, Kim K . Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int. 2009; 21(5):847-53. DOI: 10.1007/s00198-009-1024-9. View

Kun-Darbois J, Libouban H, Mabilleau G, Pascaretti-Grizon F, Chappard D . Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat. Clin Oral Investig. 2018; 22(9):2997-3006. DOI: 10.1007/s00784-018-2385-2. View

10.

Ribatti D, Maruotti N, Nico B, Longo V, Mangieri D, Vacca A . Clodronate inhibits angiogenesis in vitro and in vivo. Oncol Rep. 2008; 19(5):1109-12. DOI: 10.3892/or.19.5.1109. View

11.

Polyzos S, Anastasilakis A, Makras P, Terpos E . Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment. Exp Clin Endocrinol Diabetes. 2011; 119(9):519-24. DOI: 10.1055/s-0031-1284365. View

12.

Favia G, Pilolli G, Maiorano E . Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone. 2009; 45(3):406-13. DOI: 10.1016/j.bone.2009.05.008. View

13.

Nishida S, Fujii Y, Yoshioka S, Kikuichi S, Tsubaki M, Irimajiri K . A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci. 2003; 73(21):2655-64. DOI: 10.1016/s0024-3205(03)00664-7. View

14.

Hansen P, Knitschke M, Draenert F, Irle S, Neff A . Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment - a grossly underestimated risk?. Clin Oral Investig. 2012; 17(8):1829-37. DOI: 10.1007/s00784-012-0873-3. View

15.

Stefanucci A, Marrone A, Agamennone M . Investigation of the N-BP Binding at FPPS by Combined Computational Approaches. Med Chem. 2014; 11(5):417-31. DOI: 10.2174/1573406410666141226132630. View

16.

Carmagnola D, Canciani E, Sozzi D, Biglioli F, Moneghini L, Dellavia C . Histological findings on jaw osteonecrosis associated with bisphosphonates (BONJ) or with radiotherapy (ORN) in humans. Acta Odontol Scand. 2013; 71(6):1410-7. DOI: 10.3109/00016357.2013.765592. View

17.

Bhavsar N, Trivedi S, Dulani K, Brahmbhatt N, Shah S, Chaudhri D . Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women (12-month study). Osteoporos Int. 2016; 27(8):2611-9. DOI: 10.1007/s00198-016-3577-8. View

18.

Hoefert S, Sade Hoefert C, Munz A, Schmitz I, Grimm M, Yuan A . Effect of bisphosphonates on macrophagic THP-1 cell survival in bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Surg Oral Med Oral Pathol Oral Radiol. 2016; 121(3):222-32. DOI: 10.1016/j.oooo.2015.10.008. View

19.

Seo M, Myoung H, Lee J, Kim S, Lee S . Changes in oncogenic protein levels in peri-implant oral malignancy: a case report. Maxillofac Plast Reconstr Surg. 2019; 41(1):46. PMC: 6838285. DOI: 10.1186/s40902-019-0235-z. View

20.

Miyazaki T, Miyauchi S, Anada T, Imaizumi H, Suzuki O . Evaluation of osteoclastic resorption activity using calcium phosphate coating combined with labeled polyanion. Anal Biochem. 2010; 410(1):7-12. DOI: 10.1016/j.ab.2010.11.014. View